{"id":27187,"date":"2024-02-21T10:43:33","date_gmt":"2024-02-21T15:43:33","guid":{"rendered":"https:\/\/myeloma.ca\/?p=27187"},"modified":"2024-02-23T11:49:06","modified_gmt":"2024-02-23T16:49:06","slug":"optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/","title":{"rendered":"Optimisation du traitement d\u2019un my\u00e9lome\u202f: Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Wee-Joo Chng, MBBS, Ph.\u202fD., FRCPath, FRCP, (<em>National University Cancer Institute<\/em><em> <\/em>\u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire.&nbsp;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.myeloma.org\/videos\/optimizing-myeloma-treatment-pomalidomide-based-regimens-compared-asian-myeloma-network-amn?utm_medium=email&amp;utm_source=engagingnetworks&amp;utm_campaign=ash-recap-video&amp;utm_content=ASH+recap+video+Eblast+Final\" target=\"_blank\" rel=\"noopener\" title=\"\">Regardez la vid\u00e9o&#8230;\u00a0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wee-Joo Chng, MBBS, Ph.\u202fD., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire.&nbsp;&nbsp; Regardez la vid\u00e9o&#8230;\u00a0<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[88,53],"tags":[],"class_list":["post-27187","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire. Regardez la vid\u00e9o...\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Leigh Kinch-Pedrosa\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Optimisation du traitement d\u2019un my\u00e9lome : Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement) | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire. Regardez la vid\u00e9o...\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2024-02-21T15:43:33+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2024-02-23T16:49:06+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Optimisation du traitement d\u2019un my\u00e9lome : Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement) | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire. Regardez la vid\u00e9o...\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#blogposting\",\"name\":\"Optimisation du traitement d\\u2019un my\\u00e9lome : Comparaison des r\\u00e9gimes de traitement \\u00e0 base de pomalidomide dans l\\u2019\\u00e9tude de l\\u2019Asian Myeloma Network (AMN) \\u2013 une analyse de phase III de la combinaison PCd par rapport \\u00e0 la combinaison Pd pour traiter un my\\u00e9lome r\\u00e9cidivant-r\\u00e9fractaire (MMRR) (en anglais seulement) | My\\u00e9lome Canada\",\"headline\":\"Optimisation du traitement d\\u2019un my\\u00e9lome\\u202f: Comparaison des r\\u00e9gimes de traitement \\u00e0 base de pomalidomide dans l\\u2019\\u00e9tude de l\\u2019Asian Myeloma Network (AMN) \\u2013 une analyse de phase III de la combinaison PCd par rapport \\u00e0 la combinaison Pd pour traiter un my\\u00e9lome r\\u00e9cidivant-r\\u00e9fractaire (MMRR) (en anglais seulement)\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2024-02-21T10:43:33-05:00\",\"dateModified\":\"2024-02-23T11:49:06-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s, Actualit\\u00e9s et \\u00e9v\\u00e9nement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"position\":3,\"name\":\"Actualit\\u00e9s\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#listItem\",\"name\":\"Optimisation du traitement d\\u2019un my\\u00e9lome\\u202f: Comparaison des r\\u00e9gimes de traitement \\u00e0 base de pomalidomide dans l\\u2019\\u00e9tude de l\\u2019Asian Myeloma Network (AMN) \\u2013 une analyse de phase III de la combinaison PCd par rapport \\u00e0 la combinaison Pd pour traiter un my\\u00e9lome r\\u00e9cidivant-r\\u00e9fractaire (MMRR) (en anglais seulement)\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#listItem\",\"position\":4,\"name\":\"Optimisation du traitement d\\u2019un my\\u00e9lome\\u202f: Comparaison des r\\u00e9gimes de traitement \\u00e0 base de pomalidomide dans l\\u2019\\u00e9tude de l\\u2019Asian Myeloma Network (AMN) \\u2013 une analyse de phase III de la combinaison PCd par rapport \\u00e0 la combinaison Pd pour traiter un my\\u00e9lome r\\u00e9cidivant-r\\u00e9fractaire (MMRR) (en anglais seulement)\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/\",\"name\":\"Leigh Kinch-Pedrosa\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc9a857bcf898667f0e3d913441f25e1d2d9d652d14911323fd2e018121c78a3?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Leigh Kinch-Pedrosa\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/\",\"name\":\"Optimisation du traitement d\\u2019un my\\u00e9lome : Comparaison des r\\u00e9gimes de traitement \\u00e0 base de pomalidomide dans l\\u2019\\u00e9tude de l\\u2019Asian Myeloma Network (AMN) \\u2013 une analyse de phase III de la combinaison PCd par rapport \\u00e0 la combinaison Pd pour traiter un my\\u00e9lome r\\u00e9cidivant-r\\u00e9fractaire (MMRR) (en anglais seulement) | My\\u00e9lome Canada\",\"description\":\"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \\u2013 Singapour) discute de cet essai randomis\\u00e9 de phase III qui compare la combinaison PCd \\u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\\u2019un my\\u00e9lome multiple r\\u00e9cidivant-r\\u00e9fractaire. Regardez la vid\\u00e9o...\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/21\\\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"datePublished\":\"2024-02-21T10:43:33-05:00\",\"dateModified\":\"2024-02-23T11:49:06-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Optimisation du traitement d\u2019un my\u00e9lome : Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement) | My\u00e9lome Canada","description":"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire. Regardez la vid\u00e9o...","canonical_url":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#blogposting","name":"Optimisation du traitement d\u2019un my\u00e9lome : Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement) | My\u00e9lome Canada","headline":"Optimisation du traitement d\u2019un my\u00e9lome\u202f: Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement)","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2024-02-21T10:43:33-05:00","dateModified":"2024-02-23T11:49:06-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#webpage"},"articleSection":"Actualit\u00e9s, Actualit\u00e9s et \u00e9v\u00e9nement"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","position":2,"name":"Actualit\u00e9s et \u00e9v\u00e9nement","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","name":"Actualit\u00e9s"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#listItem","name":"Optimisation du traitement d\u2019un my\u00e9lome\u202f: Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement)"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#listItem","position":4,"name":"Optimisation du traitement d\u2019un my\u00e9lome\u202f: Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement)","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","name":"Actualit\u00e9s"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/","name":"Leigh Kinch-Pedrosa","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/bc9a857bcf898667f0e3d913441f25e1d2d9d652d14911323fd2e018121c78a3?s=96&d=mm&r=g","width":96,"height":96,"caption":"Leigh Kinch-Pedrosa"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/","name":"Optimisation du traitement d\u2019un my\u00e9lome : Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement) | My\u00e9lome Canada","description":"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire. Regardez la vid\u00e9o...","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"datePublished":"2024-02-21T10:43:33-05:00","dateModified":"2024-02-23T11:49:06-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"Optimisation du traitement d\u2019un my\u00e9lome : Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement) | My\u00e9lome Canada","og:description":"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire. Regardez la vid\u00e9o...","og:url":"https:\/\/myeloma.ca\/fr\/2024\/02\/21\/optimisation-du-traitement-dun-myelome-comparaison-des-regimes-de-traitement-a-base-de-pomalidomide-dans-letude-de-lasian-myeloma-network-amn-une-analy\/","article:published_time":"2024-02-21T15:43:33+00:00","article:modified_time":"2024-02-23T16:49:06+00:00","twitter:card":"summary_large_image","twitter:title":"Optimisation du traitement d\u2019un my\u00e9lome : Comparaison des r\u00e9gimes de traitement \u00e0 base de pomalidomide dans l\u2019\u00e9tude de l\u2019Asian Myeloma Network (AMN) \u2013 une analyse de phase III de la combinaison PCd par rapport \u00e0 la combinaison Pd pour traiter un my\u00e9lome r\u00e9cidivant-r\u00e9fractaire (MMRR) (en anglais seulement) | My\u00e9lome Canada","twitter:description":"Wee-Joo Chng, MBBS, Ph. D., FRCPath, FRCP, (National University Cancer Institute \u2013 Singapour) discute de cet essai randomis\u00e9 de phase III qui compare la combinaison PCd \u00e0 la combinaison Pd dans une population de patients asiatiques atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant-r\u00e9fractaire. Regardez la vid\u00e9o..."},"aioseo_meta_data":{"post_id":"27187","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-02-21 15:45:13","updated":"2026-04-30 08:44:04","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=27187"}],"version-history":[{"count":2,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27187\/revisions"}],"predecessor-version":[{"id":27322,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27187\/revisions\/27322"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=27187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=27187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=27187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}